Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xarelto Is The Pharma Watchword In Bayer's 3Q Update

Executive Summary

Despite Bayer AG's third quarter earnings call being heavily dominated by talk of the company's ongoing Monsanto acquisition and its recent deconsolidation of material science company Covestro, Xarelto stood out as the hot topic within the German firm's pharma division.

You may also be interested in...



Bayer Quickens Pace Of Polymers IPO, Other Non-Core Businesses Next?

Rising From The Ashes Of 2020: ‘We Must Not Waste The Learning,’ Says Dame Sally

UK special envoy on antimicrobial resistance Professor Dame Sally Davies, who is also the former chief medical officer for England, talks to In Vivo about the challenges of 2020, the importance of a strong working relationship between the public and private sectors, and reaching a turning point on AMR.

In Vivo’s Deals Of The Year 2020: Cast Your Vote!

It is time for In Vivo's 13th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.

Topics

Related Companies

UsernamePublicRestriction

Register

OM005224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel